Business Context and Reporting Period
Sunshine Biopharma Inc., a Colorado-based emerging growth company, filed this Form 8-K on August 29, 2017. The company is headquartered in Pointe-Claire, Quebec, Canada, and focuses on generic pharmaceuticals and the clinical development of its flagship anticancer compound, Adva-27a.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes
The primary material change reported is the execution of an Investment Banking Agreement with Jitney Trade Inc. on August 29, 2017. Under this agreement:
- Jitney Trade Inc. will act as the exclusive placement agent for a proposed equity financing of up to $10 million Canadian on a "best efforts" basis.
- Jitney will also serve as the sponsor for the listing of Sunshine Biopharma's Common Shares on the TSX Venture Exchange (TSX-V).
- The financing is structured as a private placement to qualified investors in Canada, relying on Regulation S exemptions.
Guidance, Outlook, and Risks
Management indicated that proceeds from the proposed financing will be utilized for the implementation of the business plan, specifically targeting Generic Pharmaceuticals operations and the Clinical Development of Adva-27a. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the inherent uncertainty of a "best efforts" financing arrangement.
Investor Verification Checklist
- Verify the status of the proposed $10 million Canadian private placement and whether the "best efforts" target was met.
- Confirm the successful listing of Common Shares on the TSX Venture Exchange.
- Review the attached Press Release (Exhibit 99.7) for additional terms of the agreement with Jitney Trade Inc.
- Monitor subsequent filings for updates on the clinical development timeline of Adva-27a.